Close this search box.

Where Roche’s obesity data fit in efficacy landscape


Roche’s CT-388 yields promising weight loss; tolerability data will be key to determining its competitive profile

By Stephen Hansen, Director of Biopharma Intelligence

May 16, 2024 5:59 PM UTC

Roche’s dual GIP/GLP-1 agonist has demonstrated a strong early efficacy signal in a Phase Ib trial, suggesting it may be tolerability that will determine how competitive CT-388 is in an increasingly crowded obesity market.

Roche (SIX:ROG; OTCQX:RHHBY) announced Thursday that once-weekly CT-388 led to placebo-adjusted weight loss of 18.8% at 24 weeks in a Phase Ib trial in adults with obesity, which is comparable to the weight loss achieved with much longer treatment with either market leader Wegovy semaglutide from Novo Nordisk A/S (CSE:NOVO-B; NYSE:NVO) or Zepbound tirzepatide from Eli Lilly and Co. (NYSE:LLY)…